Evidence map›Paper›PMID 39445393›Full record

ArticleAnalytical chemistry2024

Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses.

Julien Camperi, Brian Roper, Emily Freund, Rebecca Leylek, Ariane Nissenbaum, Carolina Galan, Roger Caothien, Zhilan Hu, Peggy Ko, Allison Lee and 5 more

Abstract read
In one paragraph

Article in Analytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Removal of dsRNA byproducts using affinity chromatography.Molecular therapy. Nucleic acids · 2025
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Julien CamperiCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0002-4020-2278
Brian RoperCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Emily FreundDepartment of Molecular Biology, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Rebecca LeylekDepartment of Immunology Discovery, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0002-3740-0361
Ariane NissenbaumDepartment of Molecular Biology, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Carolina GalanDepartment of Molecular Biology, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Roger CaothienCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Zhilan HuCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Peggy KoCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Allison LeeCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Kamalakar ChatlaCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0002-1835-710X
Luladey AyalewCell Therapy Engineering and Development, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.
Feng YangProtein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0003-0769-5573
Steffen LippoldProtein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.ORCID 0000-0002-1032-5808
Axel GuilbaudProtein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in mRNA technology have enabled mRNA-based therapies to enter a new era of medicine. Such therapies benefit from a single, standardized in vitro transcription (IVT) manufacturing process applicable to a wide range of targets. This process includes several downstream purification steps, which aim to eliminate impurities that potentially affect safety and efficacy. However, it is not fully understood which impurities are the most critical; hence, some efforts are still needed to establish the correlation between RNA impurities and their role in limiting therapeutic efficacy. To study this relationship, we produced in vitro-transcribed mRNAs using several bacteriophage T7 RNA polymerases, including one wild-type and four engineered variants. Important attributes of the mRNA such as integrity, purity, and functional activity were then measured using advanced physicochemical and cellular assays. For impurities including abortive transcripts, mRNAs containing partial poly(A) tails, and double-stranded (ds)RNA byproducts, structure-function relationships have been established by tracking cellular responses (i.e., protein expression, reactogenicity) in multiple cell models. By varying the T7 RNA polymerase, different levels of sense-antisense dsRNA byproducts were measured by mass photometry, contributing directly to immunological reactogenicity in bone marrow-derived dendritic cells. T7 RNA polymerase differences with regard to short (<20 nucleotides) 3'-loopback dsRNA byproducts were also further investigated using native mass spectrometry by precisely resolving these impurities at the nucleotide level. Overall, this study highlights the importance of developing sensitive and advanced analytical methods to characterize IVT mRNA impurities and understand their interaction with cellular machinery in order to ensure quality control of RNA-based therapies.

Indexed as

DNA-Directed RNA PolymerasesRNA, MessengerTranscription, GeneticViral ProteinsAnimalsHumansbacteriophage T7 RNA polymeraseDNA-Directed RNA PolymerasesRNA, MessengerViral Proteins

Identifiers

PMID39445393
PMCPMC11542617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.